Jonathan M. Ducore, M.D., M.P.H.

Emeritus Professor

To see if Jonathan M. Ducore is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).



Pediatric Hematology/Oncology



Locations and Contact

2279 45th Street
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Phone


Clinic Fax


Clinic Fax


Clinic Referral Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Ducore believes in treating the whole patient which includes involvement of important family members and a team-approach with nurses, social workers and  other specialists and support personnel to cover all aspects of care.

Clinical Interests

Dr. Ducore is a specialist in Cancer and Blood Disorders in Children with a special interest in diseases of blood clotting and bleeding and non-malignant (non-cancerous) disorders of the blood (anemia, low white blod cells, etc). He is involved in clinical trials of the development of new drugs and therapies (including gene therapy) in the treatment of bleeding and clotting disorders.

Research/Academic Interests

Dr. Ducore's research involves the development of nre therapies, including gene therapy to treat bleeding and clotting disorders. He also studies the epidemiology of cancer and blood diseases in children and clotting disorders in adults.


Pediatric Hematology/Oncology

Center/Program Affiliation

Center for Healthcare Policy and Research
Graduate Group in Epidemiology
UC Davis Children's Hospital
UC Davis Comprehensive Cancer Center

Undergraduate School

B.A., Rutgers University, New Brunswick NJ 1969

Medical School

M.D., Duke University School of Medicine, Durham NC 1973

Other School

M.P.H., UC Berkeley School of Public Health, Berkeley CA 2002


Pediatrics, University of Cincinnati Medical Center and Cincinnati Children's Hospital, Cincinnati OH 1973-1974


Pediatrics, University of Cincinnati Medical Center and Cincinnati Children's Hospital, Cincinnati OH 1974-1975


Molecular Oncology, Laboratory of Molecular Oncology, National Cancer Institute, National Institutes of Health, Bethesda MD 1978-1980


Pediatric Oncology, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD 1977-1978


Pediatric Hematology/Oncology, University of Colorado Medical Center and Denver Children's Hospital, Denver CO 1975-1977

Graduated Summa Cum Laude with Distinction in Zoology, 1969

Henry Rutgers Scholar, 1968, 1969

Elected, Phi Beta Kappa, 1968

Elected, Delta Phi Alpha, 1967

American Cancer Society Junior Faculty Clinical Fellowship Award, 1982, 1983, 1984, 1985

Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, Michaels LA, Linardi CCG. afety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thrombosis Research. 2019;183:13-19.

Thornburg CD, Ducore J. A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor. Haemophilia. 2019 Jan;25(1):e48-e50. doi:10.1111/hae.13646. Epub 2018 Nov 23.

George LA, Sullivan SK, Giermasz A, Ducore J, Rasko J, Samelson-Jones BJ, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Wachtel K, Galvão AM, Winters A, Galas T, van der Loo J, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Endogenous prophylaxis for hemophilia B following gene therapy with a high specific activity Factor IX variant. New England Journal of Medicine. 2017;377(23):2215-27.

Ducore J, Lawrence J, Simpson M, Boggio L, Bellon A, Burggraaf J, Stevens J, Moerland M, Frieling J, Reijers J, Wang M. Safety and Dose-Dependency of Eptacog Beta (Activated) in a Dose Escalation Study of Non-Bleeding Congenital Hemophilia A or B Patients, With or Without Inhibitors. Haemophilia. 2017;23:844-51.

Liesner RJ, Abashidze M, Aleinkova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost, H, Chan, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, GuilleL B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Immunogenicity, Efficacy and Safety of Nuwiq® (Human-cl rhFVIII) in Previously Untreated Patients with Severe Haemophilia A – Interim Results from the NuProtect Study. Haemophilia. 2017;23:1-10.

Wang M, Lawrence JB, Quon DV, Ducore J, Simpson ML, Boggio LN, Mitchell IS, Yuan G, Alexander WA, Schved J-F. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of hemophilia inhibitor-related bleeding. Haemophilia. 2017;23:832-43.

Buckner TW, Leavitt AD,Ragni,M, Kempton CL, Eyster E, Cuker A, Lentz SR, Ducore J, Leissinger C, Wang M,Key NS. Prospective, Multicenter Study of Postoperative Deep Vein Thrombosis in Patients with Haemophilia Undergoing Major Orthopedic Surgery. Thrombosis and Haemostasis. 2016;116(1):42-9.

Whitehead TP, Ward MH, Colt JS, Dahl G, Ducore J, Reiner K, Gunier RB, Hammond SK, Rappaport SM and Metayer C. Dust metal loadings and the risk of childhood lymphoblastic leukemia. Journal of Exposure Science and Environmental Epidemiology. 2015;25(6):593-8.

Ducore JM, Miguelino MG, Powell JS. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Rev Hematol. 2014;7(5):559-71.

Huang T, Ducore J. Children and adolescents with ALL are taller than expected at diagnosis. J Ped Hemat Onco. 2014;36(1):16-21.